Biomedical Research and Therapy 2026, 13(05):8634-8650

Open Access Full Text Article

Review

The Role of α-2A-Adrenergic Receptors in Modulating Epileptiform Activity and the Therapeutic Potential of Brimonidine (UK14,304)

Kabeer Abubakar[1,*], Danmaigoro Abubakar[2], Abdullahi Adamu Ja'e[3], Tawfiq Y T Zyoud[4]

ABSTRACT

Epilepsy remains a profound clinical challenge, with approximately one-third of patients exhibiting resistance to current antiseizure medications (ASMs). This persistent drug resistance highlights the limitations of traditional ion-channel targets and underscores an urgent need for alternative, mechanism-based neuromodulatory strategies. This review synthesizes current findings on the therapeutic potential of the noradrenergic system, specifically the α_2A-adrenergic receptor (α_2A-AR), as a modulator of network excitability. We examine the biology of the α_2A-AR, which acts as a presynaptic "brake" on glutamatergic transmission, and review preclinical evidence evaluating brimonidine (UK14,304) as a prototype agonist. Emerging data suggest that selective α_2A-activation offers a state-dependent antiseizure mechanism, thereby suppressing pathological hypersynchrony while sparing physiological transmission. Finally, we propose that future therapeutic success depends upon the development of biased ligands and focal delivery systems, which may effectively harness α_2A-AR signaling to suppress focal seizures and mitigate the risk of Sudden Unexpected Death in Epilepsy (SUDEP).

Key words: Brimonidine, Epileptiform activity, Antiseizure medications, SUDEP, Norepinephrine

[1]*Department of Human Anatomy, Federal University of Lafia, Nassarawa, Nigeria*

[2]*Faculty of Veterinary Medicine, Usmanu Danfodiyo University, P.M.B 2346, Sokoto, Nigeria*

[3]*Department of Human Physiology, Federal University of Lafia, Nigeria*

[4]*Department of Imaging, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia*

Correspondence

Kabeer Abubakar, Department of Human Anatomy, Federal University of Lafia, Nassarawa, Nigeria

Email: Kabeernakhadee@yahoo.com

History

- Received: Jan 17, 2026
- Accepted: May 10, 2026
- Published Online: May 31, 2026

DOI : 10.15419/bmrat.v13i5.1073

INTRODUCTION

Epilepsy is a chronic neurological disorder characterized by spontaneous, recurrent seizures resulting from abnormal, hypersynchronous neuronal activity[1]. Globally, the burden of this condition is profound: approximately 50 million people live with epilepsy, with over 5 million new cases diagnosed annually, predominantly in low- and middle-income countries[2].

To manage this condition, current antiseizure medications (ASMs) primarily target voltage-gated ion channels or modulate GABAergic and glutamatergic transmission to restore the critical balance between excitation and inhibition[3]. However, despite the introduction of newer agents, approximately one-third of patients remain drug-resistant, and many others experience adverse effects that limit long-term utility[4,5]. These persistent clinical limitations underscore an urgent need to explore alternative molecular systems that modulate epileptogenic circuits.

One promising avenue involves neuromodulatory systems that tune network excitability, such as the noradrenergic system[6]. Norepinephrine (NE) exerts powerful, state-dependent effects on cortical and hippocampal synchrony, influencing both seizure threshold and termination[7]. Among the receptors mediating these effects, the α_2A-adrenergic receptor (α_2A-AR) is particularly relevant[8]. Owing to its high expression in limbic and cortical regions, α_2A-ARs are strategically positioned to regulate glutamatergic output and network synchronization.

Consequently, pharmacological targeting of this receptor represents a promising, though complex, strategy[8]. Although activating α_2A-AR effectively reduces excitability[9], systemic agonists such as clonidine and dexmedetomidine have traditionally caused notable sedation and hypotension[10,11]. These side effects have restricted their use in long-term epilepsy treatment. Nonetheless, the therapeutic viability of this target is now being revisited through the lens of modern pharmacology. By using biased ligands that selectively activate anticonvulsant pathways without engaging sedative ones[12], or by applying focal delivery methods to target only the epileptogenic zone[13], it may be possible to capitalize on the strong antiseizure effects of the α_2A receptor while avoiding systemic side effects[14].

To understand the specific physiological functions and therapeutic possibilities of the α_2A-AR subtype within the intricate adrenergic signaling landscape, highly selective pharmacological probes are

Cite this article : Abubakar K, Abubakar D, Adamu Ja'e A, Zyoud TYT. **The Role of α-2A-Adrenergic Receptors in Modulating Epileptiform Activity and the Therapeutic Potential of Brimonidine (UK14,304)**. *Biomed. Res. Ther.* 2026, 13(05):8634-8650.

crucial. In this context, brimonidine (UK14,304) is essential to this review. Initially identified as a potent and selective α_2A-adrenoceptor agonist, it serves as a primary reference compound for studying the pharmacology of α_2A-ARs [15]. It mimics the actions of endogenous norepinephrine at these receptors. As a result, it activates $G_{\alpha i}$/o-coupled signaling pathways, which are critical for downstream effects. Activation of these pathways suppresses adenylyl cyclase, lowers cAMP signaling, and modulates ion conductance. Together, these changes decrease neuronal excitability and reduce neurotransmitter release [15]. Brimonidine exhibits neuroprotective effects in preclinical models of retinal injury and optic neuropathy, and it has gained clinical approval for ocular indications [16,17]. Because of these properties, analyzing its pharmacological profile provides vital insights into the mechanisms of targeted α_2A-adrenoceptor modulation. Such analysis also informs the translational value of α_2A-adrenoceptor-focused therapies. In experimental systems, brimonidine's neuroprotective actions include enhanced survival of retinal ganglion cells and reduced excitotoxic damage. However, definitive clinical evidence for neuroprotection in human central nervous system disorders remains limited and inconclusive [18,19]. This review aims to comprehensively evaluate current evidence on the pharmacology of α_2A-adrenoceptors, focusing on the selective agonist brimonidine as a key reference compound. The review also seeks to clarify how α_2A-adrenoceptor activation affects neuronal excitability and to assess the potential of α_2A-adrenoceptor modulation as a therapeutic strategy for future drug development.

METHODS

Literature Search Strategy and Selection Criteria

This review was conducted as a scoping review utilizing a systematic literature search. This approach was chosen to map the extent, nature, and mechanistic direction of the available evidence regarding α_2A-adrenergic receptor (α_2A-AR) signaling and the selective agonist brimonidine (UK14,304) in epilepsy, thereby identifying critical knowledge gaps for future translational work [20,21].

The review question was structured using the Population–Concept–Context (PCC) framework [22]:

- **Population**: Preclinical central nervous system (CNS) models relevant to epilepsy, including *ex vivo* brain-slice preparations, *in vivo* animal models, and mechanistic receptor-pharmacology studies.
- **Concept**: Modulation of α_2A-AR signaling, with a specific focus on the pharmacological profile of brimonidine (UK14,304).
- **Context**: Seizure-relevant biology, encompassing network excitability, glutamatergic/GABAergic transmission, epileptiform activity, seizure-linked neuroprotection, and autonomic mechanisms relevant to Sudden Unexpected Death in Epilepsy (SUDEP).

Search Strategy

Electronic literature searches were conducted in PubMed/MEDLINE, Scopus, and Web of Science from database inception through January 2026. To maximize search sensitivity, the strategy combined controlled vocabulary with free-text keywords and Boolean operators across three primary domains:

- Receptor Target: "alpha-2A adrenergic receptor," "α_2A-AR," "ADRA2A," and related α_2A-adrenoceptor terminology.
- Pharmacological Probe: "Brimonidine," "UK14,304," and related α_2A-agonist terms.
- Mechanistic Context: "epilepsy," "seizure," "epileptiform activity," "network excitability," "SUDEP," "neuromodulation," and "neuroprotection."

Additionally, the reference lists of all eligible articles and relevant seminal reviews were manually screened to capture supplemental studies not identified in the primary database query.

Eligibility Criteria

Eligibility criteria were defined *a priori*. To be included in the primary synthesis, studies were required to be peer-reviewed, English-language original research articles that met at least one of the following scientific criteria:

- *Ex vivo*, *in vivo*, or mechanistic preclinical studies evaluating the role of central α_2A-AR signaling in network excitability, synaptic transmission, epileptiform bursting, or seizure-linked autonomic dysfunction.
- Studies specifically investigating brimonidine (UK14,304) or closely related α_2A-agonists in the context of central neuroprotection, anti-seizure efficacy, or mechanisms relevant to epilepsy translation. (Note: Seminal review articles were included solely to provide conceptual background and support reference tracking, rather than serving as primary evidence).

Studies were excluded if they were conference abstracts lacking full text, editorials, commentaries, or non-English publications. To ensure the review captured the most current and highly relevant mechanistic data, preprints were universally eligible for inclusion provided they strictly met the predefined PCC criteria. However, because preprints have not yet undergone formal peer review, their findings were interpreted with appropriate methodological caution. Finally, studies were excluded if they lacked interpretable experimental controls, utilized poorly validated models preventing meaningful mechanistic interpretation, or did not clearly relate to CNS α_2A-AR biology.

Data Extraction and Synthesis

Following the removal of duplicate records, citations were screened by title and abstract, followed by a full-text review against the eligibility criteria. For each included source, data were charted regarding the study type, experimental model (species/tissue preparation), epileptogenic trigger, pharmacological intervention, comparator condition, and principal mechanistic findings. Particular analytical focus was placed on variables likely to influence pharmacological interpretation, such as the receptor subtype interrogated and whether the observed drug effects reflected global network suppression versus state-dependent modulation of pathological activity.

Due to the substantial heterogeneity in model systems, experimental designs, and endpoints across the selected literature, the evidence was synthesized narratively rather than via meta-analysis. In alignment with standard scoping review methodology, a formal quantitative risk-of-bias tool was not applied[21,22]. However, the methodological rigor of the included studies—specifically model validity, pharmacological specificity, and the use of appropriate controls—was assessed qualitatively throughout the synthesis to ensure robust evidence mapping (Figure 1).

The selection process and the number of records identified, screened, and included are detailed in the PRISMA-ScR flow diagram (Figure 2). Furthermore, the characteristics, models, and principal findings of the included preclinical studies are charted in Table 1 to support the data extraction process.

A_2A-ADRENERGIC RECEPTOR BIOLOGY

The Adrenergic System

The adrenergic system is a central regulator of cardiovascular function, metabolism, and arousal[23]. Its primary agonists are the catecholamines norepinephrine (NE) and epinephrine, synthesized sequentially from tyrosine in adrenal chromaffin cells and noradrenergic neurons[24]. While epinephrine acts primarily as a circulating hormone, NE serves as the principal neurotransmitter in the brain[6]. Noradrenergic neurons, located primarily in the locus coeruleus, project widely to the cortex, hippocampus, and amygdala. Following release, NE is cleared via reuptake and metabolism, a process that tightly regulates noradrenergic tone.

Adrenergic Receptors and the α_2A Subtype

Adrenergic receptors are G protein-coupled receptors (GPCRs) classified into α1, α2, and β families[25]. Functionally, these receptors diverge significantly: α1 receptors couple to Gq/11 to increase excitability, whereas β receptors couple to Gs to stimulate cAMP production[26]. In contrast, the α2 family (α_2A, α2B, α2C) couples to Gi/o proteins to exert inhibitory effects[11].

The α_2A-AR is the predominant subtype in the CNS[27]. Mechanistically, agonist binding inhibits adenylyl cyclase via $G_{\alpha i}$/o, reducing cAMP/PKA activity. Concurrently, Gβγ subunits inhibit voltage-gated $Ca2^{+}$ channels (VGCCs) and activate G-protein-gated inwardly rectifying K^{+} (GIRK) channels[28,29]. Through these combined actions, α_2A-AR activation hyperpolarizes neurons and suppresses neurotransmitter release. Recent structural studies have identified key residues for ligand binding, facilitating the design of biased ligands that may optimize these signaling pathways[12].

CNS Distribution

Immunohistochemical studies reveal a strategic distribution of α_2A-ARs in seizure-relevant circuits[30]. In the brainstem, they function as autoreceptors on the locus coeruleus to regulate NE firing[29]. In the forebrain, specifically the hippocampus and neocortex, they are located on presynaptic terminals of Schaffer collaterals and inhibitory interneurons[31]. Ultrastructural analysis confirms their localization on presynaptic boutons, supporting their role in gating excitatory transmission[31].



Figure 1: Conceptual framework and methodological workflow of the scoping review. The review process was structured across four distinct phases to map the preclinical literature regarding α_2A-adrenergic receptor (α_2A-AR) signaling in epilepsy. **Phase 1** defines the study parameters using the Population, Concept, Context (PCC) framework. **Phase 2** illustrates the literature identification, screening, and selection pipeline, including database queries, deduplication, and the application of predefined eligibility criteria (with an explicit, predefined inclusion for a highly relevant mechanistic preprint). **Phase 3** outlines the data extraction parameters and qualitative methodological appraisal, conducted without formal quantitative risk-of-bias tools. **Phase 4** summarizes the final deliverables, culminating in a narrative synthesis, concept clarification, and a translational roadmap for future clinical applications. *Abbreviations: CNS, central nervous system; SUDEP, sudden unexpected death in epilepsy.*

Table 1: Characteristics and Principal Findings of Key Preclinical Studies Investigating α_2A-AR Modulation

Study Year	Experimental Model/Preparation	Intervention/ Target	Principal Preclinical Findings
Jurgens et al. (2007).	*Ex vivo* rat hippocampal slice (CA3 disinhibition model)	α_2A-AR activation	Demonstrated that α_2A-AR activation acts directly on recurrent excitatory networks to effectively reduce spontaneous epileptiform burst frequency.
Janumpalli et al. (2008).	*In vivo* transgenic mice (D79N point mutation of α_2A-AR)	Endogenous norepinephrine	Confirmed that the α_2A-AR subtype is explicitly required for the antiepileptogenic and seizure-restraining actions of endogenous norepinephrine.
Avoli et al. (2002).	*Ex vivo* hippocampal slice (4-aminopyridine model)	Pharmacological network mapping	Characterized the 4-AP model as a mixed-synaptic state where both excitatory and GABAergic signaling actively drive complex epileptiform synchronization.
Fujita et al. (2013). & Maciulaitiene et al. (2024)	*In vivo* murine optic nerve injury/crush models	Brimonidine (UK14,304)	Demonstrated robust, direct central neuroprotective properties, promoting neuronal survival, ERK1/2 signaling, and axon growth following acute injury.
Zhang et al. (2021).	*In vivo* DBA/1 mice (SUDEP model)	α2-adrenergic agonists	Showed that enhancing α2-adrenergic tone significantly mitigates seizure-induced respiratory arrest and prevents fatal cardiorespiratory collapse.
Biggane et al. (2022).	*Ex vivo* rat hippocampal slice	α_2A-AR specific ligands	Provided quantitative pharmacological characterization of ligand efficacy, confirming robust suppression of CA3 epileptiform activity via α_2A-ARs.
Fink et al. (2023). & Xu et al. (2022)	*In vivo* murine models & Structural assays	Biased α_2A-agonists (Gi/o preference)	Demonstrated that structure-guided ligands can preferentially activate Gi/o pathways (anticonvulsant/analgesic) while avoiding β-arrestin recruitment (sedation).
Abubakar & Ivanov (2025). *(Preprint)*	*Ex vivo* adult mouse hippocampal slice (4-AP model)	Brimonidine (UK14,304)	Demonstrated state-dependent modulation, showing that α_2A-AR agonism preferentially dampens pathological network synchronization while sparing baseline physiological synaptic responses.
Jurgens et al. (2005).	*Ex vivo* rat hippocampal slices (electrophysiological recordings of spontaneous network activity in the CA3 region).	Pharmacological modulation of adrenergic receptors (evaluating the distinct effects of endogenous norepinephrine alongside specific α1-, α2-, and β-adrenergic receptor agonists and antagonists).	Demonstrated that norepinephrine exerts opposing modulatory effects on CA3 network excitability depending on the receptor subtype engaged. Specifically, activation of **α2-adrenergic receptors** potently suppresses spontaneous epileptiform burst frequency, whereas activation of β-adrenergic receptors increases network burst frequency. This highlights α2-ARs as the primary inhibitory driver of adrenergic seizure suppression in this local circuit.
Ahmed et al. (2001)	*In vivo* adult rat model of acutely increased intraocular pressure (glaucoma model evaluating retinal ganglion cell survival).	Brimonidine (selective α2-adrenergic receptor agonist).	Demonstrated that brimonidine exerts a significant, direct neuroprotective effect on adult rat retinal ganglion cells following ischemic injury induced by elevated intraocular pressure. This highlights the neuroprotective capacity of α2-AR agonism beyond its purely hemodynamic or pressure-lowering effects.

Qu et al. (2019)	*In* vitro structural biology utilizing X-ray crystallography to determine the high-resolution atomic structure of the human α_2A-adrenergic receptor.	Structural and mutational analysis of the α_2A-adrenergic receptor (α_2A-AR) in complex with a partial agonist and an antagonist to identify specific molecular determinants for ligand binding and G-protein coupling.	Successfully determined the crystal structures of the α_2A-AR. The study identified key non-conserved amino acid residues spanning from the ligand-binding pocket (Phe7.39 and Tyr6.55) to the intracellular G-protein coupling region (Ile34.51 and Lys34.56). It demonstrated that these specific residues govern the interplay between partial agonism and biased signaling, providing the critical structural blueprint needed for the rational design of next-generation, highly selective, or pathway-biased α_2A-AR therapeutics.
Tavares et al. (1996)	*Ex vivo* rat brain tissue (sagittal and coronal sections) utilizing RNase protection assays and highly sensitive in situ hybridization with single-stranded RNA riboprobes.	Mapping the neuroanatomical localization and subtype-specific mRNA expression of the **α_2A-** and **α2B-adrenergic receptors** across distinct brain structures.	Demonstrated that both α_2A- and α2B-AR mRNAs are widely distributed throughout the brain. The study found that α_2A-AR expression is generally much greater than α2B-AR expression in most central areas (including the cerebral cortex, cerebellum, pons-medulla, and hypothalamus). Notably, this study successfully detected α_2A-AR mRNA in the thalamus, the trigeminal nucleus, and both the granule and molecular layers of the cerebellum, highlighting the expansive neuroanatomical footprint of the α_2A subtype.
Shen et al. (2020)	*In vivo* DBA/1 mouse model of audiogenic seizures, which is a highly validated preclinical model used to study seizure-induced respiratory arrest (SIRA) and Sudden Unexpected Death in Epilepsy (SUDEP).	Modulation of the central noradrenergic system (investigating endogenous norepinephrine deficiency and evaluating pharmacological interventions aimed at enhancing norepinephrine transmission to prevent SIRA).	Demonstrated that a critical deficiency in central norepinephrine transmission is a primary driver of seizure-induced respiratory arrest (SIRA) in DBA/1 mice. Crucially, the study showed that pharmacologically enhancing noradrenergic tone successfully restored respiratory function and prevented SIRA. This establishes a vital translational link between central adrenergic signaling and the prevention of fatal respiratory collapse, highlighting the neuroprotective potential of targeting these pathways in SUDEP.
Tan et al. (2002)	*In vivo* transgenic mouse model (specifically, mice heterozygous for the α_2A-adrenergic receptor, which mimics a state of reduced receptor reserve or lower receptor density).	Pharmacological comparison of full versus partial α_2A-adrenergic receptor agonists to evaluate the impact of receptor reserve on therapeutic efficacy and side-effect profiles.	Demonstrated that in a state of reduced receptor reserve, partial α_2A-AR agonists can successfully decouple desired therapeutic effects from dose-limiting side effects. Specifically, the study showed that while full agonists caused severe sedation and cardiovascular depression (bradycardia), partial agonists maintained their target therapeutic efficacy with a significantly widened therapeutic window. This provides crucial *in vivo* evidence supporting the rational design of partial agonists to avoid systemic side effects.

Sitnikova et al. (2023)	*In vivo* preclinical models of absence epilepsy (specifically genetic models like WAG/Rij rats) utilize electroencephalographic (EEG) recordings to monitor generalized spike-wave discharges (SWDs) within the thalamocortical circuitry.	Pharmacological modulation of α2-adrenergic receptors (evaluating both systemic agonists and antagonists) to determine their specific influence on thalamocortical network excitability and the generation of absence seizures.	Demonstrated a critical, network-specific caveat to α2-AR pharmacology: activation of α2-ARs potently *aggravates* and provokes spike-wave discharges (absence seizures), whereas α2-AR antagonists suppress them. This highlights that the antiseizure efficacy of α2-AR agonists is highly dependent on the seizure type and neural circuit; while they are protective in focal/limbic networks (like the hippocampus), they are strongly pro-convulsant in the thalamocortical networks mediating absence epilepsy.
Szot et al. (1999)	*In vivo* transgenic mouse model utilizing Dbh -/- mice (which lack dopamine β-hydroxylase and are therefore completely deficient in endogenous norepinephrine) subjected to various chemoconvulsant (kainic acid, pentylenetetrazol, flurothyl) and sensory (audiogenic) seizure-inducing stimuli.	Investigating the fundamental physiological role of the central noradrenergic system by comparing seizure thresholds, propagation, and survival rates between norepinephrine-deficient mice and wild-type controls.	Demonstrated definitively that endogenous norepinephrine serves as a critical, broad-spectrum anticonvulsant mechanism in the brain. The study found that norepinephrine-deficient mice exhibited significantly increased susceptibility to all tested seizure-inducing stimuli, displaying lower seizure thresholds, dramatically more severe seizure phenotypes, and higher seizure-induced mortality compared to wild-type mice.

α-2A Adrenoceptor Functions

The molecular identification of different adrenoceptor subtypes spurred research into subtype-selective agents to improve therapeutic effectiveness and reduce off-target effects. Gene targeting studies show that the α_2A adrenoceptor subtype is responsible for many of the classical pharmacological effects linked to non-selective α_2 agonists like clonidine[32]. In transgenic mouse models, activating α_2A-adrenoceptors has been associated with hypotension and bradycardia. These responses are diminished or absent when α_2A receptors are genetically disrupted, setting them apart from other α_2 subtypes[32]. Additionally, α_2A adrenoceptors play a role in sedation and the central nervous system depressant effects caused by α_2 agonists[32]. Neuronal α_2A receptors in the prefrontal cortex are linked to enhanced working memory and cognitive control after selective α_2A activation in primate models[33,34]. Although α_2 agonists like clonidine and dexmedetomidine have pain-relieving properties, the involvement of various receptor subtypes and neural pathways makes it difficult to attribute these effects solely to α_2A-adrenoceptors[35].

Pre- and Postsynaptic Mechanisms

Presynaptically, α_2A-ARs act as ”brakes” on synaptic transmission[36]. As autoreceptors, they inhibit NE release via negative feedback. As heteroreceptors on glutamatergic terminals, they significantly reduce excitatory postsynaptic potentials (EPSPs) by suppressing presynaptic Ca2+ entry[36]. Crucially, this inhibition is more pronounced at excitatory synapses than GABAergic synapses, allowing for a net reduction in network excitability[36]. Postsynaptically, α_2A-AR activation opens GIRK channels, generating an outward K+ current that hyperpolarizes pyramidal neurons and dampens their response to depolarizing inputs[37]. Collectively, these receptors act as dynamic gain controllers (Figure 3), regulating the transformation of synaptic inputs into spiking output[38].

THE ROLE OF A_2A-ARS IN CNS EXCITABILITY AND EPILEPSY

Glutamatergic and GABAergic Imbalance

Seizures arise when the balance between glutamate-mediated excitation and GABA-mediated inhibition



Figure 2: PRISMA-ScR flow diagram of the study selection process. A systematic literature search across PubMed, Scopus, and Web of Science yielded 138 initial records. Following the removal of 15 duplicates, 123 unique records were screened by title and abstract, resulting in the exclusion of 30 irrelevant studies. During the eligibility phase, 93 full-text articles were assessed against the predefined criteria. Of these, 16 were excluded for reasons including lack of full text, language, model validity, or lacking a specific focus on central nervous system α_2A-AR biology. Ultimately, 77 preclinical studies met all criteria and were included in the final scoping review.

is disrupted[39,40]. Under physiological conditions, glutamate activates N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors to drive depolarization, while GABA activates $GABA_A$ and $GABA_B$ receptors to hyperpolarize neurons[41]. In epilepsy, this homeostasis is lost; reduced GABAergic inhibition or excessive glutamatergic drive leads to runaway excitation and excitotoxicity[42]. While current ASMs target these systems directly, their broad modulation often results in cognitive side effects, necessitating more selective neuromodulatory approaches[43].

Noradrenergic Modulation of Epileptiform Activity

The noradrenergic system intersects with these primary signaling pathways to modulate seizure sus-



Figure 3: Pre- and Postsynaptic Mechanisms Underlying Synaptic Transmission. This schematic illustrates key presynaptic and postsynaptic processes involved in neurotransmission, including vesicle docking and release at the presynaptic terminal, receptor activation on the postsynaptic membrane, and subsequent ion flux that contributes to synaptic signaling.

ceptibility[44]. Evidence indicates that NE generally exerts anticonvulsant effects; NE-deficient mice exhibit increased seizure susceptibility, which is reversed by restoring NE synthesis[7,44]. However, the effect is receptor-dependent: α1 activation can be proconvulsant during stress, and β activation may facilitate excitability[45]. Conversely, α_2A-AR activation consistently suppresses glutamate release and inhibits epileptiform activity[9]. This receptor-specific dichotomy suggests that selective α_2A targeting can harness the anticonvulsant potential of NE while avoiding the proconvulsant actions of other adrenergic subtypes[8,45].

PHARMACOLOGY AND ACTIONS OF BRIMONIDINE (UK14,304)

Clinical Pharmacology and Translational Pharmacokinetics

Brimonidine (UK-14,304) was synthesized as an α2-adrenoceptor-selective imidazoline agonist with reduced lipophilicity compared to clonidine, theoretically to minimize blood-brain barrier (BBB) penetration and consequent sedation[46]. However, experimental and clinical data indicate that brimonidine retains pharmacologically significant central nervous system (CNS) access. In pediatric patients, topical ophthalmic administration has precipitated lethargy, unresponsiveness, apnea, bradycardia, and hypotension, confirming its central activity[47,48]. Furthermore, animal models demonstrate that radiolabeled brimonidine reaches the optic nerves, optic tracts, and olfactory bulb following ocular dosing, despite negligible systemic blood concentrations. BBB-permeation studies further corroborate brimonidine's measurable capacity to cross into the CNS[49,50]. Therefore, brimonidine should be viewed as a ligand with limited but defined brain penetrance, rather than a compound entirely excluded from the CNS.

Importantly, merely increasing BBB penetration would not improve the drug's therapeutic index due to the complex autonomic biology of α2-adrenoceptors. Gene-targeting studies reveal that brainstem α_2A-receptors mediate the canonical hypotensive response, whereas peripheral α2B-receptors in vascular smooth muscle mediate vasoconstriction, which can counteract central hypotension[51,52]. Reflecting this mixed cardiovascular profile, even unilateral topical brimonidine elicits measurable reductions in systemic blood pressure and heart rate in adults[53]. This highlights the potent peripheral and systemic effects of the drug, which parallel its established clinical utility in lowering intraocular pressure via specific receptor cascades (Figure 4). Therefore, optimizing this drug class requires achieving CNS target engagement while minimizing both central sympatholysis and peripheral vascular receptor occupancy.

Consequently, future brimonidine-inspired ligands must be optimized across receptor subtype, signaling bias, and pharmacokinetic exposure dimensions.



Figure 4: Pharmacological Profile and Physiological Actions of the Selective α2-adrenoceptor Agonist brimonidine (UK-14,304). Brimonidine is a potent and selective α2-adrenoceptor agonist utilized both as a pharmacological reference tool and a therapeutic agent. Agonist binding to Gi/o-coupled α2-adrenoceptors activates signaling cascades that suppress neuronal excitability and neurotransmitter release. This is mediated primarily through $G_{\alpha i}$-dependent inhibition of adenylyl cyclase and cAMP production, alongside Gβγ-dependent inhibition of voltage-gated Ca^{2+} channels and activation of G protein-coupled inwardly-rectifying K^+ (GIRK) channels. Clinically, brimonidine is indicated for lowering intraocular pressure (IOP). This therapeutic effect is attributed to a dual mechanism involving suppressed aqueous humor production and increased uveoscleral outflow.

First, candidate molecules should exhibit selectivity for the α_2A-subtype over α2B in both binding affinity and intrinsic efficacy. Brimonidine's functional α2-selectivity is driven largely by this efficacy differential rather than an absolute affinity gap. Second, next-generation ligands must circumvent the broad, high-efficacy signaling profile of canonical imidazoline agonists. Brimonidine and dexmedetomidine function as robust agonists for both G protein activation and β-arrestin-2 recruitment at the human α_2A-receptor. Conversely, recently developed structure-guided α_2A-agonists exhibit preferential Gi/o signaling with negligible β-arrestin recruitment, preserving in vivo analgesia without inducing sedation[53]. While it remains to be definitively proven that biased signaling eliminates hypotension, this establishes a clear medicinal chemistry directive: preserve orthosteric interactions required for α_2A activation while avoiding conformations linked to broad transducer engagement. Recent cryo-electron microscopy (cryo-EM) structures of the α_2A-receptor offer a template for this targeted design, highlighting conserved binding-pocket residues such as $D128^{3.32}$, $Y431^{7.43}$, and $F427^{7.39}$ [54].

Third, pharmacokinetic optimization must prioritize unbound brain exposure over crude lipophilicity. In CNS drug discovery, the unbound brain-to-plasma partition coefficient is a superior metric to nominal BBB permeability, as it accounts for the net effects of influx, efflux, and non-specific tissue binding[55]. An optimal brimonidine successor requires sufficient unbound CNS exposure to engage α_2A-dependent neuroprotective or spinal circuits, alongside low unbound plasma concentrations to limit systemic α2-receptor occupancy[56]. Furthermore, emerging research suggests that mitigating cardiovascular liability may require circuit-level modulation rather than exclusively intensifying α_2A agonism. For instance, ADRIANA, a recently identified α2B-selective antagonist, elevates spinal noradrenaline and induces α_2A-dependent analgesia without cardiovascular side effects in murine and non-human primate models[57]. This underscores a

critical design principle: future CNS-active therapeutics must integrate robust brain exposure with α_2A-selective efficacy and peripheral α2B sparing, rather than pursuing global α2-adrenoceptor agonism.

Neuroprotection and Neuromodulation

Beyond its ocular effects, brimonidine exhibits neuroprotective properties[58]. In optic nerve injury models, it promotes neuronal survival via ERK1/2 signaling and suppression of inflammatory pathways[59]. In the context of epilepsy, the drug's ability to penetrate neural tissue and robustly activate Gi/o signaling makes it an attractive candidate for suppressing pathological excitation[60].

PRECLINICAL EVIDENCE IN EPILEPTIC MODELS

Hippocampal Slice Models

Ex vivo hippocampal slice studies confirm the anticonvulsant properties of brimonidine, but understanding its true mechanism requires comparing distinct epileptogenic models. In early CA3 models, epileptiform bursting was induced by pharmacologically impairing GABAergic inhibition. Under these disinhibited conditions, α_2A-adrenergic receptor (α_2A-AR) activation successfully reduced spontaneous burst frequency. This demonstrates that α_2A-ARs can suppress hyperexcitability directly by attenuating the recurrent excitatory CA3 network, rather than merely restoring lost GABAergic tone[9,38]. However, the pharmacological landscape shifts significantly when epileptiform activity is induced by 4-aminopyridine (4-AP). Unlike standard disinhibition models, 4-AP blocks voltage-gated potassium channels, which broadly enhances neurotransmitter release from both excitatory and inhibitory terminals. Consequently, the 4-AP model preserves and actively recruits GABAergic signaling into the epileptiform pattern. In hippocampal slices, 4-AP generates complex synchronous activity, ranging from fast CA3-driven glutamatergic interictal events to slower GABA-dependent discharges[61]. Evaluating a drug in this environment tests its efficacy in a circuit where excitation, inhibition, and propagation dynamics remain intact and highly complex.

This model-specific context clarifies recent findings regarding brimonidine's efficacy. In adult mouse hippocampal slices treated with 4-AP, brimonidine significantly increased the interval between interictal-like discharges while leaving physiological synaptic responses largely unchanged[62]. This targeted response reflects state-dependent modulation. In the older CA3 model, α_2A-AR signaling is tested against a simplified substrate where recurrent excitation dominates. In the 4-AP model, the same receptor system is tested in a mechanistically mixed epileptiform state, where preserved inhibitory signaling reshapes the drug's apparent effect. Ultimately, comparing these ex vivo studies indicates that brimonidine is not acting as a uniform central nervous system depressant. Its efficacy heavily depends on the pathological state of the network. When challenged by the robust, mixed-synaptic hyperactivity of the 4-AP model, α_2A-AR agonism preferentially dampens pathological network synchronization while sparing baseline physiological transmission[9,61,62]. This state-dependency provides a vital theoretical framework for how α_2A-agonists might control focal seizures without indiscriminately suppressing normal hippocampal function.

SUDEP and Mortality Models

Beyond seizure suppression, the noradrenergic system is critical for preventing Sudden Unexpected Death in Epilepsy (SUDEP)[63]. In DBA/1 mice, a well-established model of SUDEP, deficiencies in norepinephrine synthesis correlate with seizure-induced respiratory arrest[63]. Pharmacological interventions that enhance noradrenergic tone or activate α2-adrenergic receptors have been shown to reduce the incidence of respiratory arrest significantly[14]. While clonidine, a non-selective α2 agonist, was utilized in these studies, the high density of α_2A receptors in brainstem respiratory centers suggests this subtype may play a predominant role in maintaining respiratory drive during ictal events[14]. Thus, α2-adrenergic modulation offers a potential dual therapeutic benefit: mitigating cortical hyperexcitability and preventing fatal cardiorespiratory collapse.

Targeted Delivery

To circumvent the systemic side effects of α2 agonists (e.g., hypotension), novel delivery systems are under investigation[13]. Approaches such as electrophoretic drug delivery allow for focal, on-demand administration of ASMs directly to the epileptogenic zone[13]. Applying such technologies to brimonidine could maximize local antiseizure efficacy while minimizing peripheral exposure (Proctor et al., 2018).

THERAPEUTIC IMPLICATIONS AND FUTURE DIRECTIONS

The evidence reviewed supports α_2A-ARs as high-value targets for next-generation epilepsy therapies (Löscher et al., 2013). To translate this potential into clinical practice, several strategic avenues must be pursued (Figure 5):

Subtype-Selective and Biased Ligands

Leveraging structural biology to design "biased" agonists that favor G-protein anticonvulsant pathways over β-arrestin pathways linked to sedation [12]. Recent advances in G protein-coupled receptor (GPCR) structural biology have fundamentally transformed the approach to targeting the α_2A-adrenergic receptor. Traditional agonists, such as clonidine and brimonidine, act as "balanced" ligands; they uniformly recruit both Gi/o protein signaling pathways (which mediate the desired presynaptic anticonvulsant effects) and β-arrestin-2 pathways (which are heavily implicated in dose-limiting adverse events, such as profound sedation and cardiovascular depression). The proposal that future therapeutic success lies in "biased" agonism is rooted in the pharmacological ability to decouple these distinct intracellular cascades. Current evidence indicates that α_2A-adrenoceptor activation is the subtype most directly linked to anticonvulsant effects, as α_2A signaling suppresses epileptiform activity and contributes to endogenous seizure restraint [9,64,65]. However, effective seizure control does not require indiscriminate activation of all downstream pathways. Studies in mice show that sedative responses to α2 agonists are influenced by arrestin-associated signaling machinery, whereas partial α_2A activation can preserve selected physiological effects without proportionate sedation [66,67]. By leveraging high-resolution cryo-electron microscopy (cryo-EM) structures of the human α_2A-receptor in its active state, drug discovery has moved from empirical screening to rational, structure-guided design (Xu et al., 2022). For example, recent large-scale computational docking campaigns have successfully identified novel, non-imidazoline α_2A-agonists that exhibit profound signaling bias. These molecules preferentially trigger Gi/o signaling with virtually undetectable β-arrestin recruitment [68].

At the molecular level, this functional selectivity is achieved by engineering ligands that selectively interact with specific conserved residues within the orthosteric binding pocket—most notably D128$^{3.32}$, Y431$^{7.43}$, and F427$^{7.39}$ [12,68]. By finely tuning the steric and electrostatic contacts with these specific amino acids, medicinal chemists can stabilize a distinct receptor conformation. This precise conformation permits the intracellular loops to engage G proteins but sterically hinders the intracellular structural rearrangements required for β-arrestin coupling. In preclinical *in vivo* models, these structure-derived biased ligands successfully preserved centrally mediated analgesia without inducing sedation [68]. Applying this structural paradigm to epilepsy represents a highly promising translational frontier. Engineering biased α_2A-agonists could theoretically isolate the state-dependent suppression of epileptiform discharges from the systemic sympatholytic and sedative burdens that have historically precluded the chronic systemic use of these drugs in clinical neurology.

Focal Delivery Systems

Utilizing intracranial catheters or implantable devices to deliver α_2A agonists specifically to seizure foci, beneficial for drug-resistant focal epilepsies [13]. Systemic administration of α_2A-agonists is heavily restricted by dose-limiting peripheral cardiovascular effects and generalized sedation. To circumvent these translational barriers, future strategies must leverage focal delivery systems to treat drug-resistant focal epilepsies. This approach utilizes intracranial catheters or implantable micro-infusion pumps to deliver α_2A-agonists directly into the precisely mapped epileptogenic zone. By bypassing the blood-brain barrier and systemic circulation, focal delivery achieves high, sustained therapeutic drug concentrations exactly where pathological hypersynchrony originates [69]. Furthermore, advancing these implantable devices could allow for integration with responsive neurostimulation (RNS) technology, creating a closed-loop system that triggers micro-infusions of the drug only upon the detection of pre-seizure electrophysiological biomarkers [70]. Ultimately, restricting α_2A-AR activation exclusively to the seizure focus maximizes the local anticonvulsant efficacy while entirely eliminating the peripheral sympatholytic and broad cognitive side effects that have historically limited this drug class.

Adjunctive Therapy

Employing low-dose α_2A agonists alongside standard ASMs to enhance seizure control and reduce SUDEP risk without compounding side effects [14]. Monotherapy with standard antiseizure



Figure 5: α_2A-Adrenergic Receptor-Mediated Neuromodulation and Its Anti-Epileptic Effects. This schematic illustrates the neuromodulatory pathways initiated by the activation of central α_2A-adrenergic receptors (α_2A-ARs). Both endogenous norepinephrine and the selective pharmacological agonist brimonidine (UK14,304) drive α_2A-AR activation via Gi/o-coupled modulation. This targeted activation results in Central Nervous System (CNS) neuromodulation that serves an anti-epileptic role by driving key therapeutic effects: enhanced inhibitory synaptic transmission, suppression of excess excitatory signaling, attenuation of epileptiform discharges, and neuroprotection and epilepsy protection. Ultimately, these targeted mechanistic pathways yield overall outcomes that include a reduced frequency of epileptic discharges, the promotion of optic nerve regeneration, and the restoration of excitatory-inhibitory balance.

medications (ASMs) frequently fails to achieve complete seizure freedom or requires high doses that cause intolerable cognitive impairment. Employing low-dose α_2A-agonists as an adjunctive therapy offers a highly synergistic pharmacological approach. Because standard ASMs predominantly target postsynaptic ion channels or GABAergic pathways, the addition of a presynaptic α_2A-agonist provides a complementary mechanism to further attenuate pathological glutamate release. Importantly, utilizing this drug class at a low dose enhances seizure control while avoiding the profound sedation and hypotension that typically preclude high-dose α2-agonist monotherapy. Furthermore, this adjunctive strategy may actively mitigate the risk of Sudden Unexpected Death in Epilepsy (SUDEP). SUDEP is fundamentally driven by massive, seizure-induced autonomic dysregulation, including severe post-ictal sympathetic storms and fatal cardiac arrhythmias[71]. Because α_2A-receptors function as central sympatholytics, their targeted activation can dampen these catastrophic neurocardiac reflexes, potentially offering a dual-action therapy that reduces both seizure frequency and the likelihood of fatal autonomic collapse[72].

Disease Modification

Investigating whether the neuroprotective pathways activated by UK14,304 can retard epileptogenesis or prevent network reorganization[58]. Current antiseizure medications are overwhelmingly symptomatic; they suppress seizures but do not alter the underlying pathological progression of the disease. A critical frontier in epilepsy research is determining whether the neuroprotective properties of α_2A-agonists, such as brimonidine, can offer true disease modification. Epileptogenesis—the process by which a normal brain develops chronic epilepsy following an initial insult like status epilepticus or trauma—is fundamentally driven by acute glutamate excitotoxicity, neuroinflammation, and subsequent aberrant network reorganization, including mossy fiber sprouting and neuronal death[73]. Because α_2A-agonists potently inhibit presynaptic glutamate release, they directly mitigate the primary driver of excitotoxic cell damage. Furthermore, preclinical studies across various neurodegeneration and brain injury models demonstrate that α2-adrenoceptor activation upregulates neurotrophic factors and activates anti-apoptotic cellular cascades[74,75]. By combining this robust anti-

excitotoxic action with direct cellular neuroprotection, future translational research must investigate whether early intervention with α_2A-agonists can successfully arrest epileptogenesis and prevent pathological network rewiring, ultimately altering the natural history of the disease rather than merely masking its symptoms.

Clinical Translation and Biomarker-Driven Trials

Bridging the translational gap between rodent *ex vivo* models and human focal epilepsy requires rigorous, proof-of-concept clinical trial designs. Currently, clinical evidence for α_2A-mediated neuroprotection or seizure suppression in the human central nervous system remains limited and inconclusive [18,19]. To overcome this barrier, future early-phase trials must integrate robust, quantifiable biomarkers rather than relying solely on patient-reported seizure diaries. Non-invasive tools, such as high-density electroencephalography (hdEEG), should be utilized to quantify targeted reductions in interictal epileptiform discharges following acute drug administration. Furthermore, neuroimaging techniques like receptor-specific positron emission tomography (PET) can be deployed to confirm central target engagement and verify that the drug reaches the necessary brain structures at therapeutic concentrations.

In addition to non-invasive biomarkers, translational neurology must leverage specialized clinical environments. "Window of opportunity" (or Phase 0) trials in the epilepsy monitoring unit represent an ideal framework for testing novel α_2A-agonists [76]. In these studies, patients with drug-resistant focal epilepsy who are undergoing invasive intracranial EEG (iEEG) monitoring are evaluated to assess the acute effects of the drug. This setup allows clinicians to directly and precisely measure the drug's local efficacy in suppressing pathological bursting within the exact human epileptogenic zone, overcoming the well-documented limitations and inaccuracies of patient-reported seizure diaries [77]. Additionally, if the patient proceeds to surgical resection, the removed brain tissue can undergo molecular analysis to verify α_2A-AR pathway activation. By combining precise iEEG electrophysiological readouts with direct molecular validation, these trial designs can firmly establish the therapeutic window of α_2A-AR modulation before advancing to large-scale, chronic systemic trials [73,76].

CONCLUSION

In summary, the α-2A adrenergic receptor represents a mechanistically distinct target for seizure control, offering a way to modulate the "gain" of neural circuits. Brimonidine (UK14,304) serves as a powerful proof-of-concept molecule, demonstrating that selective α_2A activation can inhibit pathological discharges while sparing physiological transmission. Future translational success will depend on optimizing delivery methods and developing biased ligands to dissociate the potent antiseizure effects from systemic cardiovascular risks. If achieved, α_2A-AR modulation could significantly expand the therapeutic toolkit for drug-resistant epilepsy.

ABBREVIATIONS

α_2A-AR: α_2A-adrenergic receptor; **ADRA2A**: Adrenoceptor Alpha 2A gene; **AMPA**: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; **ASM**: antiseizure medication; **BBB**: blood-brain barrier; **Ca^{2+}**: calcium ion; **cAMP**: cyclic adenosine monophosphate; **CNS**: central nervous system; **Cryo-EM**: cryo-electron microscopy; **EPSP**: excitatory postsynaptic potential; **GABA**: gamma-aminobutyric acid; **GIRK**: G protein-coupled inwardly rectifying potassium channel; **GPCR**: G protein-coupled receptor; **hdEEG**: high-density electroencephalography; **iEEG**: intracranial electroencephalography; **IOP**: intraocular pressure; **K^+**: potassium ion; **NE**: norepinephrine; **NMDA**: N-methyl-D-aspartate; **PCC**: Population–Concept–Context; **PET**: positron emission tomography; **PRISMA-ScR**: Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews; **RNS**: responsive neurostimulation; **SIRA**: seizure-induced respiratory arrest; **SUDEP**: Sudden Unexpected Death in Epilepsy; **SWDs**: spike-wave discharges; **VGCC**: voltage-gated calcium channel.

ACKNOWLEDGMENTS

The authors would like to acknowledge the support and efforts of the Petroleum Technology Development Fund (PTDF), Nigeria, for their sponsorship.

AUTHOR'S CONTRIBUTIONS

All equally contributed to this work, read and approved the final manuscript.

FUNDING

None.

AVAILABILITY OF DATA AND MATERIALS

Not applicable.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

DECLARATION OF GENERATIVE AI AND AI-ASSISTED TECHNOLOGIES IN THE WRITING PROCESS

The authors declare that they have not used generative AI (a type of artificial intelligence technology that can produce various types of content including text, imagery, audio and synthetic data).

COMPETING INTERESTS

The authors declare that they have no competing interests.

REFERENCES

1. Magazi DS, Nkohla S, Mmako MT. Epilepsy seizure types, classification, and treatment. South African Family Practice. 2018;60(4):22–27. Available from: https://doi.org/10.4102/safp.v60i4.4901.
2. Beghi E, Giussani G, Abd-Allah F, Abdela J, Abdelalim A, Abraha HN, et al. Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2019 Apr;18(4):357–375. PMID: 30773428. Available from: https://doi.org/10.1016/S1474-4422(18)30454-X.
3. Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020 May;168:107966. PMID: 32120063. Available from: https://doi.org/10.1016/j.neuropharm.2020.107966.
4. Kwan P, Brodie MJ. Early identification of refractory epilepsy. New England Journal of Medicine. 2000 Feb;342(5):314–319. PMID: 10660394. Available from: https://doi.org/10.1056/NEJM200002033420503.
5. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurology. 2018 Mar;75(3):279–286. PMID: 29279892. Available from: https://doi.org/10.1001/jamaneurol.2017.3949.
6. Smythies J. Section III. The norepinephrine system. International Review of Neurobiology. 2005;64(05):173–211. PMID: 16096022. Available from: https://doi.org/10.1016/S0074-7742(05)64003-2.
7. Szot P, Weinshenker D, White SS, Robbins CA, Rust NC, Schwartzkroin PA, et al. Norepinephrine-deficient mice have increased susceptibility to seizure-inducing stimuli. Journal of Neuroscience. 1999 Dec;19(24):10985–10992. PMID: 10594079. Available from: https://doi.org/10.1523/JNEUROSCI.19-24-10985.1999.
8. Sitnikova E, Rutskova E, Smirnov K. Alpha2-Adrenergic Receptors as a Pharmacological Target for Spike-Wave Epilepsy. International Journal of Molecular Sciences. 2023 Jan;24(2):1477. PMID: 36674992. Available from: https://doi.org/10.3390/ijms24021477.
9. Jurgens CW, Hammad HM, Lichter JA, Boese SJ, Nelson BW, Goldenstein BL, et al. α2A adrenergic receptor activation inhibits epileptiform activity in the rat hippocampal CA3 region. Molecular Pharmacology. 2007 Jun;71(6):1572–1581. PMID: 17341653. Available from: https://doi.org/10.1124/mol.106.031773.
10. Cimolai N. A review of neuropsychiatric adverse events from topical ophthalmic brimonidine. Human & Experimental Toxicology. 2020 Oct;39(10):1279–1290. PMID: 32347114. Available from: https://doi.org/10.1177/0960327120918307.
11. Giovannitti JAJ, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesthesia Progress. 2015;62(1):31–39. PMID: 25849473. Available from: https://doi.org/10.2344/0003-3006-62.1.31.
12. Xu J, Cao S, Hübner H, Weikert D, Chen G, Lu Q, et al. Structural insights into ligand recognition, activation, and signaling of the α2A adrenergic receptor. Science Advances. 2022;8(9):1–12. Available from: https://doi.org/10.1126/sciadv.abj5347.
13. Proctor CM, Slézia A, Kaszas A, Ghestem A, Del Agua I, Pappa AM, et al. Electrophoretic drug delivery for seizure control. Science Advances. 2018 Aug;4(8):eaau1291. PMID: 30167463. Available from: https://doi.org/10.1126/sciadv.aau1291.
14. Zhang R, Tan Z, Niu J, Feng HJ. Adrenergic α2 receptors are implicated in seizure-induced respiratory arrest in DBA/1 mice. Life Sciences. 2021;284:1–13. Available from: https://doi.org/10.1016/j.lfs.2021.119912.
15. Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Therapeutics and Clinical Risk Management. 2006 Dec;2(4):337–346. PMID: 18360646. Available from: https://doi.org/10.2147/tcrm.2006.2.4.337.
16. Ahmed FA, Hegazy K, Chaudhary P, Sharma SC. Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Research. 2001 Sep;913(2):133–139. PMID: 11549376. Available from: https://doi.org/10.1016/S0006-8993(01)02759-7.
17. Wheeler LA, Woldemussie E. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. European Journal of Ophthalmology. 2001;11(7 Suppl 2):S30–S35. PMID: 11592528. Available from: https://doi.org/10.1177/112067210101102S03.
18. Galanopoulos A, Goldberg I. Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension. Clinical Ophthalmology. 2009;3(1):117–122. PMID: 19668554.
19. Saylor MBA, McLoon LK, Harrison AR, Lee MS. Experimental and Clinical Evidence for Brimonidine as an Optic Nerve and Retinal Neuroprotective Agent. Archives of Ophthalmology. 2009;127(4):402–406. PMID: 19365015. Available from: https://doi.org/10.1001/archophthalmol.2009.9.
20. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. International Journal of Social Research Methodology. 2005 Feb;8(1):19–32.
21. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Annals of Internal Medicine. 2018 Oct;169(7):467–473.
22. Munn Z, Peters MD, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Medical Research Methodology. 2018 Nov;18(1):143.
23. Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nature Reviews Neuroscience. 2009 Mar;10(3):211–223. PMID: 19190638. Available from: https://doi.org/10.1038/nrn2573.
24. Westfall TC. Sympathomimetic Drugs and Adrenergic Receptor Antagonists. Encyclopedia of Neuroscience. 2009;p. 685–695.

25. Qu L, Zhou Q, Xu Y, Guo Y, Chen X, Yao D, et al. Structural Basis of the Diversity of Adrenergic Receptors. Cell Reports. 2019 Dec;29(10):2929–2935.e4. PMID: 31801060. Available from: https://doi.org/10.1016/j.celrep.2019.10.088.
26. Ciccarelli M, Santulli G, Pascale V, Trimarco B, Iaccarino G. Adrenergic receptors and metabolism: role in development of cardiovascular disease. Frontiers in Physiology. 2013 Oct;4:265. PMID: 24106479. Available from: https://doi.org/10.3389/fphys.2013.00265.
27. Tavares A, Handy DE, Bogdanova NN, Rosene DL, Gavras H. Localization of α2A-and α2B-adrenergic receptor subtypes in brain. Hypertension. 1996 Mar;27(3):449–455.
28. Chabre O, Conklin BR, Brandon S, Bourne HR, Limbird LE. Coupling of the α2A-adrenergic receptor to multiple G-proteins. A simple approach for estimating receptor-G-protein coupling efficiency in a transient expression system. Journal of Biological Chemistry. 1994 Feb;269(8):5730–5734. PMID: 7907086. Available from: https://doi.org/10.1016/S0021-9258(17)37522-1.
29. Gilsbach R, Albarrán-Juárez J, Hein L. Pre- versus postsynaptic signaling by α(2)-adrenoceptors. Current Topics in Membranes. 2011;67:139–160. PMID: 21771489. Available from: https://doi.org/10.1016/B978-0-12-384921-2.00007-0.
30. Rosin DL. Distribution of α2A-and α2C-adrenergic receptor immunoreactivity in the central nervous system. Adrenergic Receptor Protocols. 2000;p. 475–505.
31. Milner TA, Lee A, Aicher SA, Rosin DL. Hippocampal α2a-adrenergic receptors are located predominantly presynaptically but are also found postsynaptically and in selective astrocytes. Journal of Comparative Neurology. 1998 Jun;395(3):310–327. PMID: 9596526. Available from: https://doi.org/10.1002/(SICI)1096-9861(19980808)395:3<310::AID-CNE4>3.0.CO;2-5.
32. Gilsbach R, Hein L. Are the pharmacology and physiology of α2-adrenoceptors determined by α2-heteroreceptors and autoreceptors respectively? British Journal of Pharmacology. 2012 Jan;165(1):90–102.
33. Franowicz JS, Kessler LE, Borja CM, Kobilka BK, Limbird LE, Arnsten AF. Mutation of the α2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. Journal of Neuroscience. 2002 Oct;22(19):8771–8777.
34. Arnsten AF. The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Review of Neurotherapeutics. 2010 Oct;10(10):1595–1605. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf. PMID: 20925474. Available from: https://doi.org/10.1586/ern.10.133.
35. Baker JG, Balaji P, Bond RA, Bylund DB, Eikenburg DC, Graham RM, et al. Adrenoceptors in GtoPdb v. 2023.3. IUPHAR/BPS Guide to Pharmacology CITE. 2023 Nov;2023(3).
36. Boehm S. Presynaptic α2-adrenoceptors control excitatory, but not inhibitory, transmission at rat hippocampal synapses. Journal of Physiology. 1999 Sep;519(Pt 2):439–449. PMID: 10457061. Available from: https://doi.org/10.1111/j.1469-7793.1999.0439m.x.
37. Lüscher C, Slesinger PA. Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. Nature Reviews Neuroscience. 2010 May;11(5):301–315. PMID: 20389305. Available from: https://doi.org/10.1038/nrn2834.
38. Jurgens CW, Boese SJ, King JD, Pyle SJ, Porter JE, Doze VA. Adrenergic receptor modulation of hippocampal CA3 network activity. Epilepsy Research. 2005;66(1-3):117–128. PMID: 16140503. Available from: https://doi.org/10.1016/j.eplepsyres.2005.07.007.
39. Sumadewi KT, Harkitasari S, Tjandra DC. Biomolecular mechanisms of epileptic seizures and epilepsy: a review. Acta Epileptologica. 2023 Nov;5(1):28. PMID: 40217521. Available from: https://doi.org/10.1186/s42494-023-00137-0.
40. Bradford HF. Glutamate, GABA and epilepsy. Progress in Neurobiology. 1995 Dec;47(6):477–511. PMID: 8787032. Available from: https://doi.org/10.1016/0301-0082(95)00030-5.
41. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacological Reviews. 2010 Sep;62(3):405–496. PMID: 20716669. Available from: https://doi.org/10.1124/pr.109.002451.
42. Jefferys JG, De Curtis M, Avoli M. Neuronal network synchronization and limbic seizures. Epilepsia. 2010;51(s5 Suppl. 5):19. Available from: https://doi.org/10.1111/j.1528-1167.2010.02805.x.
43. Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nature Reviews Drug Discovery. 2013 Oct;12(10):757–776. PMID: 24052047. Available from: https://doi.org/10.1038/nrd4126.
44. Weinshenker D, Szot P, Miller NS, Rust NC, Hohmann JG, Pyati U, et al. Genetic comparison of seizure control by norepinephrine and neuropeptide Y. Journal of Neuroscience. 2001 Oct;21(19):7764–7770. PMID: 11567066. Available from: https://doi.org/10.1523/JNEUROSCI.21-19-07764.2001.
45. Niitani K, Ito S, Wada S, Izumi S, Nishitani N, Deyama S, et al. Noradrenergic stimulation of α1 adrenoceptors in the medial prefrontal cortex mediates acute stress-induced facilitation of seizures in mice. Scientific Reports. 2023 May;13(1):8089. PMID: 37208473. Available from: https://doi.org/10.1038/s41598-023-35242-0.
46. Fairbanks CA, Stone LS, Wilcox GL. Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis. Pharmacology & Therapeutics. 2009 Aug;123(2):224–238. PMID: 19393691. Available from: https://doi.org/10.1016/j.pharmthera.2009.04.001.
47. Tamilvanan S, Abdulrazik M, Benita S. Non-systemic delivery of topical brimonidine to the brain: a neuro-ocular tissue distribution study. Journal of Drug Targeting. 2006 Jan;14(10):670–679. Available from: https://doi.org/10.1080/10611860600992157.
48. Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. Journal of AAPOS. 2001 Oct;5(5):281–284. PMID: 11641636. Available from: https://doi.org/10.1067/mpa.2001.117571.
49. Proudman RG, Akinaga J, Baker JG. The signaling and selectivity of α-adrenoceptor agonists for the human α2A, α2B and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors. Pharmacology Research & Perspectives. 2022 Oct;10(5):e01003.
50. Vucicevic J, Nikolic K, Dobričić V, Agbaba D. Prediction of blood–brain barrier permeation of α-adrenergic and imidazoline receptor ligands using PAMPA technique and quantitative-structure permeability relationship analysis. European Journal of Pharmaceutical Sciences. 2015 Feb;68:94–105.
51. Hein L, Altman JD, Kobilka BK. Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission. Nature. 1999 Nov;402(6758):181–184. PMID: 10647009. Available from: https://doi.org/10.1038/46040.
52. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE. Central hypotensive effects of the α2A-adrenergic receptor subtype. Science. 1996 Aug;273(5276):801–803.
53. Yüksel N, Karabaş L, Altıntaş Ö, Yildirim Y, Çağlar Y. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure. Ophthalmologica. 2002 Feb;216(1):45–49.
54. Xu J, Cao S, Hübner H, Weikert D, Chen G, Lu Q, et al. Structural insights into ligand recognition, activation, and signaling of the α2A adrenergic receptor. Science Advances. 2022 Mar;8(9):eabj5347. Available from: https://doi.org/10.1126/sciadv.abj5347.
55. Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharmaceutical Research. 2008 Aug;25(8):1737–1750.

56. Loryan I, Reichel A, Feng B, Bundgaard C, Shaffer C, Kalvass C, et al. Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain — a Game Changing Parameter for CNS. Drug Discovery and Development. 2022;p. 1321–1341.
57. Toyomoto M, Kurihara T, Nakagawa T, Inoue A, Kimura R, Kii I, et al. Discovery and development of an oral analgesic targeting the α2B adrenoceptor. Proceedings of the National Academy of Sciences. 2025 Aug;122(32):e2500006122.
58. Fujita Y, Sato A, Yamashita T. Brimonidine promotes axon growth after optic nerve injury through Erk phosphorylation. Cell Death & Disease. 2013 Aug;4(8):e763. PMID: 23928702. Available from: https://doi.org/10.1038/cddis.2013.298.
59. Maciulaitiene R, Kalesnykas G, Pauza DH, Januleviciene I. A combination of topical and systemic administration of brimonidine is neuroprotective in the murine optic nerve crush model. PLoS One. 2024 Aug;19(8):e0308671. PMID: 39116180. Available from: https://doi.org/10.1371/journal.pone.0308671.
60. Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs & Aging. 1998 Mar;12(3):225–241. PMID: 9534022. Available from: https://doi.org/10.2165/00002512-199812030-00005.
61. Avoli M, D'Antuono M, Louvel J, Köhling R, Biagini G, Pumain R, et al. Network and pharmacological mechanisms leading to epileptiform synchronization in the limbic system in vitro. Progress in Neurobiology. 2002 Oct;68(3):167–207. PMID: 12450487. Available from: https://doi.org/10.1016/S0301-0082(02)00077-1.
62. Ahmadirad N, Fathollahi Y, Janahmadi M, Ghasemi Z, Shojaei A, Rezaei M, et al. The role of α adrenergic receptors in mediating the inhibitory effect of electrical brain stimulation on epileptiform activity in rat hippocampal slices. Brain Research. 2021 Aug;1765:147492.
63. Shen Y, Ma H, Lu H, Zhao H, Sun J, Cheng Y, et al. Deficiency of Norepinephrine Transmission In Brain Contributed To Seizure-Induced Respiratory Arrest And Is Implicated in ADHD with SUDEP In DBA/1 mice. bioRxiv. 2019 Dec;p. 865691.
64. Janumpalli S, Butler LS, MacMillan LB, Limbird LE, McNamara JO. A point mutation (D79N) of the α2A adrenergic receptor abolishes the antiepileptogenic action of endogenous norepinephrine. Journal of Neuroscience. 1998 Mar;18(6):2004–2008.
65. Biggane JP, Xu K, Goldenstein BL, Davis KL, Luger EJ, Davis BA, et al. Pharmacological characterization of the α2A-adrenergic receptor inhibiting rat hippocampal CA3 epileptiform activity: comparison of ligand efficacy and potency. Journal of Receptors and Signal Transduction Research. 2022 Dec;42(6):580–587. PMID: 35984443. Available from: https://doi.org/10.1080/10799893.2022.2110896.
66. Tan CM, Wilson MH, MacMillan LB, Kobilka BK, Limbird LE. Heterozygous α2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists. Proceedings of the National Academy of Sciences USA. 2002 Sep;99(19):12471–12476. PMID: 12205290. Available from: https://doi.org/10.1073/pnas.122368499.
67. Wang Q, Zhao J, Brady AE, Feng J, Allen PB, Lefkowitz RJ, et al. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science. 2004 Jun;304(5679):1940–1944.
68. Fink EA, Xu J, Hübner H, Braz JM, Seemann P, Avet C, et al. Structure-based discovery of nonopioid analgesics acting through the α2A-adrenergic receptor. Science. 2022 Sep;377(6614):eabn7065.
69. Cook M, Murphy M, Bulluss K, D'Souza W, Plummer C, Priest E, et al. Anti-seizure therapy with a long-term, implanted intra-cerebroventricular delivery system for drug-resistant epilepsy: A first-in-man study. EClinicalMedicine. 2020 May;22:100326. PMID: 32395709. Available from: https://doi.org/10.1016/j.eclinm.2020.100326.
70. Heiss JD, Argersinger DP, Theodore WH, Butman JA. Convection-Enhanced Delivery of Muscimol in Patients with Drug-Resistant Epilepsy. Unspecified Journal. 2018;0(0):1–12.
71. Costagliola G, Orsini A, Coll M, Brugada R, Parisi P, Striano P. The brain–heart interaction in epilepsy: implications for diagnosis, therapy, and SUDEP prevention. Annals of Clinical and Translational Neurology. 2021 Jul;8(7):1557–1568.
72. Schilling WP, McGrath MK, Yang T, Glazebrook PA, Faingold CL, Kunze DL. Simultaneous cardiac and respiratory inhibition during seizure precedes death in the DBA/1 audiogenic mouse model of SUDEP. PLoS One. 2019 Oct;14(10):e0223468.
73. Löscher W. The holy grail of epilepsy prevention: preclinical approaches to antiepileptogenic treatments. Neuropharmacology. 2019 Apr;p. 107605. PMID: 30980836. Available from: https://doi.org/10.1016/j.neuropharm.2019.04.011.
74. Sysoev YI, Prikhodko VA, Chernyakov RT, Idiyatullin RD, Musienko PE, Okovityi SV. Effects of Alpha-2 Adrenergic Agonist Mafedine on Brain Electrical Activity in Rats after Traumatic Brain Injury. Brain Sciences. 2021;.
75. Kimura A, Namekata K, Guo X, Noro T, Harada C, Harada T. Targeting oxidative stress for treatment of glaucoma and optic neuritis. Oxidative Medicine and Cellular Longevity. 2017;2017(1):2817252. Available from: https://doi.org/10.1155/2017/2817252.
76. Vogelbaum MA, Krivosheya D, Borghei-Razavi H, Sanai N, Weller M, Wick W, et al. Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neuro-Oncology. 2020 Nov;22(11):1568–1579.
77. Goldenholz DM, Tharayil JJ, Kuzniecky R, Karoly P, Theodore WH, Cook MJ. Simulating clinical trials with and without intracranial EEG data. Epilepsia Open. 2017 Jun;2(2):156–161. Available from: https://doi.org/10.1002/epi4.12038.